
Acalabrutinib/Venetoclax With or Without Obinutuzumab Earns Positive CHMP Opinion for Untreated CLL
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for acalabrutinib (Calquence) plus venetoclax with or without obinutuzumab (Gazyva) for the treatment of adult patients with previously …